Reducing Adult Smoking: FDA Needs to Lead the Charge

Nov.28.2022
Reducing Adult Smoking: FDA Needs to Lead the Charge
US teen e-cigarette use declines, however, adult smoking still needs to see progress in reducing numbers.

Author Background: Dr. Matthew Holman is the Vice President in charge of regulatory strategy for PMI in the United States. Prior to joining Philip Morris in September, Holman served as the Director of the Office of Science at the FDA's Center for Tobacco Products.


Source: Duluth News Tribune, image provided by Matthew Holman.


The latest data from the National Youth Tobacco Survey tells a story that you may not have heard before. The U.S. Food and Drug Administration and Centers for Disease Control and Prevention recently released the results of the 2022 survey, which showed a decrease in underage e-cigarette use to levels below the "epidemic" announced by the FDA in 2018. The data shows a continued reversal of the trend.


According to the same data, the percentage of teenagers smoking combustible cigarettes is at its lowest historical level of 1.6%. In fact, over the past few years, there has been a significant decrease in the use of all tobacco products among adolescents. Many stakeholders, including myself, have tirelessly worked towards reducing underage usage and have achieved success.


However, according to data from the American Cancer Society, the decrease in the number of adult smokers has not matched this progress, with 34 million smokers currently in the United States.


The FDA could do more to help Americans quit smoking and should engage in conversations with smokers again, just like it did before releasing the 2018 Tobacco Survey results.


Smoking among adults has also decreased, although not significantly, much like among teenagers. According to public health data, smoking remains the largest single preventable cause of death in the United States. Therefore, while acknowledging the significant progress made in recent years in reducing tobacco use among youths is important, it is equally important to recognize that too many Americans still smoke.


As a senior professional at the FDA for 20 years and recently appointed as the top scientist for the agency's Center for Tobacco Products, I am aware that it is home to talented scientists who want to do more to help smokers make better choices than continuing to smoke - while also preventing underage nicotine use.


So, what can be done to speed up the reduction of adult smoking in the United States? The US public health agencies need to adopt a more balanced approach in promoting tobacco and nicotine products, which is an urgently needed and important strategic move.


The FDA has invested a significant amount of funds in launching multiple multimedia campaigns aimed at reducing underage electronic cigarette use among adolescents and parents. These efforts should continue. However, what is completely missing is similar investment in communicating with adult smokers. The FDA must engage smokers in a consistent, transparent, and meaningful way to help them quit smoking altogether or encourage those who don't quit to switch to innovative smoke-free products. The FDA acknowledges that such products are a better alternative to continuing smoking. Let's make sure adult smokers know this.


The message that all Americans need to hear from health experts is simple: if you don't currently use tobacco products, don't start. If you smoke, quitting is the best option. If you don't quit, switch to smoke-free alternatives. This message is scientifically supported, and the FDA's authorization of nicotine products confirms this. For adult smokers who completely switch to nicotine products, the chance of exposure to harmful chemicals in smoke is significantly reduced, and for certain products, the risk of lung cancer and other smoking-related diseases may be decreased.


Today, smokers are not receiving this crucial message, and that needs to change. Otherwise, nearly 500,000 Americans will continue to die unnecessarily every year. Health experts have a responsibility to proactively share information about better choices with adult smokers, while also continuing to prevent underage tobacco use.


When I was working at the FDA, Commissioner Scott Gottlieb announced a comprehensive plan aimed at getting smokers to switch from traditional combustible cigarettes to less harmful tobacco products or to quit tobacco altogether. The plan was unveiled over five years ago, but until now, the FDA's efforts have primarily focused on preventing underage use. It is now time to take action to assist adult smokers in making better choices.


I hope that my former colleagues at the FDA, who are all exceptional public health scientists, will take necessary action to accelerate the transition towards a healthier America by keeping smokers away from cigarettes.


Statement:


This article is sourced from compiled third-party information and is intended solely for industry exchange and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the accuracy of the content. The translation of this article is solely intended for industry communication and research.


Due to limitations in the translator's skills, the translated article may not accurately reflect the original text. Please consider the original text as the primary source.


2FIRSTS is fully aligned with the position and stance of the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's regional vape retail restrictions are expanding. State Duma Speaker Vyacheslav Volodin said on November 7 that 17 regions had adopted decisions to ban vape sales, while another 39 were preparing or considering similar legislation. On November 12, lawmakers in Leningrad Oblast and the Republic of Karelia adopted bans scheduled to begin on March 1, 2027. A day earlier, St. Petersburg unanimously approved a five-year ban proposal in its first reading. The city has 615 specialist vape shops and more than 2,400 other retail outlets selling vaping products alongside other goods. Under Federal Law No. 186-FZ, enacted in June 2026, Russian regions may prohibit retail sales of electronic nicotine delivery systems and related liquids between March 2027 and March 2032. The legislation also restricts licensed suppliers from delivering covered products to retail premises in regions where bans apply.
Regulations
Nov.13
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
NATO Executive Director David Spross Sees U.S. Vape Regulation Improving, Calls for More PMTA Authorizations and Warns of 2027 State Tax Pressure
The National Association of Tobacco Outlets is calling for more FDA marketing authorizations, greater transparency in the PMTA process and continued enforcement against unauthorized e-cigarettes, even as its executive director, David Spross, points to recent regulatory developments as signs of progress. At the state level, excise taxes, flavor restrictions and vapor product directories remain major issues for tobacco retailers. By August 2026, 17 states had enacted laws establishing state-managed e-cigarette directories or similar systems.
Innovation
Sep.29 by 2Firsts Perspectives
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands' NGP Revenue Rises 11.4% in FY2026 but Business Still Posts £63 Million Loss; Zone Reaches 114,000 US Stores as Smokeless Reporting Takes Shape
Imperial Brands reported an 11.4% increase in next-generation product (NGP) net revenue to £419 million in fiscal 2026, while its adjusted NGP operating loss narrowed to £63 million. European NGP revenue rose 16.8%, while the Americas recorded a 17.1% decline. Global modern oral nicotine volumes increased 27.8%, with US nicotine pouch brand Zone expanding to approximately 114,000 stores. The company also acquired Black Buffalo in the US and Helwit in Sweden, broadening its oral nicotine portfolio. From FY2027, Imperial Brands will adopt a new Smokeless reporting category combining NGP with traditional oral tobacco. On the new basis, FY2026 Smokeless net revenue was £554 million, with adjusted operating profit of £14 million.
company
Nov.18
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India Steps Up Nicotine Pouch Enforcement as ZYN, White Fox Circulate and Drug Panel Urges Halt to New Nicotine Formulations
India's Ministry of Health and Family Welfare has directed states to step up enforcement against nicotine pouch sales, citing increased availability through online and offline channels and concern about nicotine exposure among children. Reuters reported that international brands including ZYN and White Fox are being sold in India. A study led by ICMR-NICPR found pouches in seven of 10 surveyed locations and identified 68 brands and 445 flavors online. Separately, India's Drugs Technical Advisory Board recommended in August that no new nicotine formulation be approved.
Regulations
Sep.28 by 2Firsts Perspectives